PAPER Mackin RS, Nelson JC, Delucchi KL, Raue PJ, Satre DD, Kiosses DN, Alexopoulos GS, Arean PA
SEARCH RESULTS
330029 RESULTS
PAPER González-Colaço Harmand M, Meillon C, Rullier L, Avila-Funes JA, Bergua V, Dartigues JF, Amieva H
Cognitive decline after entering a nursing home: a 22-year follow-up study of institutionalized and noninstitutionalized elderly people.
J Am Med Dir Assoc. 2014 Jul;15(7):504-8. Epub 2014 Mar 26 PubMed: 24679926PAPER Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H
On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson's Psychosis.
Neurochem Res. 2014 Mar 30; PubMed: 24682754PAPER Schapansky J, Nardozzi JD, Felizia F, LaVoie MJ
Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy.
Hum Mol Genet. 2014 Aug 15;23(16):4201-14. Epub 2014 Mar 27 PubMed: 24682598PAPER Bhidayasiri R, Mekawichai P, Jitkritsadakul O, Panyakaew P, Kaewwilai L, Boonrod N, Petchrutchatachart S, Jagota P, Boonpeng K, Singmaneesakulchai S, Setthawatcharawanich S
Nocturnal journey of body and mind in Parkinson's disease: the manifestations, risk factors and their relationship to daytime symptoms. Evidence from the NIGHT-PD study.
J Neural Transm. 2014 Mar 31; PubMed: 24682359PAPER Campbell AW
Parkinson's Disease: A Brief Review.
Adv Mind Body Med. 2014 Spring;28(2):4-5. PubMed: 24681998PAPER Smith KM, Dahodwala N
Sex differences in Parkinson's disease and other movement disorders.
Exp Neurol. 2014 Mar 28; PubMed: 24681088PAPER Wu Y, Guo XY, Wei QQ, Song W, Chen K, Cao B, Ou RW, Zhao B, Shang HF
Determinants of the quality of life in Parkinson's disease: results of a cohort study from Southwest China.
J Neurol Sci. 2014 May 15;340(1-2):144-9. Epub 2014 Mar 14 PubMed: 24679837PAPER Nordberg A, Forsberg A, Engler H
Amyloid imaging in MCI patients
Neurobiol Aging 2006; 27(Suppl 1):S6.Tatiana Marcal
San Francisco Clinical Research CenterSan Francisco
PBT2 Takes a Dive in Phase 2 Alzheimer’s Trial
RESEARCH NEWS 2014-04-01 Research News On March 31, the Australian company Prana Biotechnology announced negative top-line results of its only Phase 2 study of the anti-amyloid drug PBT2. Called IMAGINE, the trial had enrolled 42 people with prodromal or mild Alzheimer’s disease
Jinte Middeldorp
Stanford University
PAPER Hegde ML, Anitha S, Jagannatha KS
Are Monomer-Oligomer Aggregates of Amyloidogenic Peptides Toxic Species in Neurodegeneration
Neurobiol Aging 2004; 25(Suppl 2):S170.PAPER Bliwise DL, Hughes M, McMahon PM, Kutner N
Observed sleep/wakefulness and severity of dementia in an Alzheimer's disease special care unit.
J Gerontol A Biol Sci Med Sci. 1995 Nov;50(6):M303-6. PubMed: 7583801Ana Silva
University of São PauloBrazil
Current Filters
No filters selected